Mark W. Frohlich

Mark W. Frohlich discloses dealings in 3 companies, chiefly Dendreon Corp, Juno Therapeutics, Inc. and Rigel Pharmaceuticals Inc. We count 91 filings; the first trade dates from 17 January 2008 and the latest from 23 May 2025.

In open-market terms, that means 1 purchase worth €70k on one side and 28 sales worth €4.5M on the other. Netting one side against the other leaves €4.5M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 32 share grants and 22 option exercises.

On 28 May 2025 came the latest disclosure, a share grant in Rigel Pharmaceuticals Inc. The last insider purchase was made public on 21 July 2010, 5,954 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.